SCHEMBL8701957

SCHEMBL8701957

CCCCCCCCCCCCCCCCCCC(=O)ON1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.52
NAAA Q02083 2/20 0.50
DGKA P23743 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 3/20 0.47
PAM P19021 2/20 0.46
MAPT P10636 2/20 0.44
MAPK1 P28482 1/20 0.44
CES2 O00748 3/20 0.43
CES1 P23141 3/20 0.43
TSHR P16473 2/20 0.43
ALDH1A1 P00352 2/20 0.42
DNM1 Q05193 1/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42
GPR84 Q9NQS5 1/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8432368 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A
SCHEMBL8433337 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A
SCHEMBL8707361 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A
SCHEMBL8433929 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A
SCHEMBL8430001 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A
SCHEMBL8707982 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A
SCHEMBL8430031 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A
SCHEMBL8704760 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A
SCHEMBL8431983 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A
SCHEMBL8433938 1.00 L3MBTL1 (0.52) L3MBTL1NAAADGKAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0844000-A1 Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis SANKYO COMPANY LIMITED (JP) 1998-05-27 EP disclosed
US-5556864-A TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0600717-A1 Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis SANKYO COMPANY LIMITED (JP) 1994-06-08 EP disclosed